ArticleEClinicalMedicine2025

Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study.

Tomasz Wróbel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.